Barr Pharmaceuticals will resubmit a request to sell its morning-after contraceptive, Plan B, without a prescription, the company said after meeting with FDA officials last Tuesday.
Barr spokeswoman Carol Cox told Reuters the company intends to have a submission back into the FDA in the next two weeks.
In a letter sent to Barr earlier this month, the FDA said it would re-examine sales of Plan B without a prescription, proposing that pills would be kept behind pharmacy counters so that women would need to ask for them. Women younger than 18 still would need a prescription. In the letter, the FDA said it hoped to within weeks wrap up Barr's application, which has lingered at the agency since 2003.
Cox and FDA spokeswoman Susan Bro described Tuesday’s meeting as “productive.”